Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Enapotamab vedotin · 1 trial · 8 indications
| Name | Type | Description |
|---|---|---|
| Enapotamab vedotin (HuMax-AXL-ADC) | BIOLOGICAL | Enapotamab vedotin (HuMax-AXL-ADC) will be administered intravenously. |
Top 20 of 59 competitors
Enapotamab vedotin is an investigational monoclonal antibody being studied for the treatment of ovarian cancer. It is currently in Phase 2 clinical development. The drug is being evaluated in oncology, specifically for patients with solid tumors, including ovarian cancer.
Enapotamab vedotin is an antibody-drug conjugate that targets AXL, a receptor tyrosine kinase. It is designed to deliver a cytotoxic agent to AXL-expressing tumor cells. The drug is being developed by Genmab A/S for the treatment of ovarian cancer and other solid tumors.
Enapotamab vedotin is being developed by Genmab A/S, a biotechnology company. Genmab is publicly traded under the ticker symbol GMAB. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with solid tumors.
Enapotamab vedotin is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of ovarian cancer and other solid tumors.
Enapotamab vedotin has been studied in a clinical trial with the identifier NCT02988817. This trial, titled 'Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors,' was a Phase 1/Phase 2 study that has been completed. The trial enrolled 306 patients with various solid tumors, including ovarian cancer.
Yes, Enapotamab vedotin is also known as HuMax-AXL-ADC. This alternative name was used in the clinical trial title for the safety study of the drug in patients with solid tumors. Both names refer to the same investigational antibody-drug conjugate being developed by Genmab.